Long term adjuvant therapy for primary breast cancer.
作者信息
Bulbrook R D
出版信息
BMJ. 1996 Feb 17;312(7028):389-90. doi: 10.1136/bmj.312.7028.389.
Abstract
摘要
相似文献
1
Long term adjuvant therapy for primary breast cancer.原发性乳腺癌的长期辅助治疗。
BMJ. 1996 Feb 17;312(7028):389-90. doi: 10.1136/bmj.312.7028.389.
2
Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.芳香化酶抑制剂在乳腺癌辅助治疗中的应用：在他莫昔芬之前、替代他莫昔芬，还是超越他莫昔芬
J Clin Oncol. 2005 Aug 1;23(22):4850-2. doi: 10.1200/JCO.2005.03.904. Epub 2005 Jul 11.
3
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.促黄体生成素释放激素激动剂用于绝经前妇女早期乳腺癌的辅助治疗。
Cochrane Database Syst Rev. 2008 Oct 8(4):CD004562. doi: 10.1002/14651858.CD004562.pub3.
4
Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.芳香化酶抑制剂作为乳腺癌辅助治疗：在临床实践中以总生存期与无病生存期作为主要终点
J Clin Oncol. 2009 Dec 10;27(35):e255-6; author reply e257-8. doi: 10.1200/JCO.2009.25.3914. Epub 2009 Nov 2.
5
Efficacy of tamoxifen as treatment of breast cancer.
Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-48-S1-54.
6
Should adjuvant chemotherapy be used in elderly women (> or = 70 years) with breast cancer? Contra.
Tumori. 2002 Jan-Feb;88(1 Suppl 1):S91-2. doi: 10.1177/030089160208800128.
7
LHRH-agonist versus chemotherapy in premenopausal breast cancer?绝经前乳腺癌中促黄体生成素释放激素激动剂与化疗的比较？
Eur J Cancer. 2002 Nov;38 Suppl 6:S45-6. doi: 10.1016/s0959-8049(02)00282-4.
8
Adjuvant tamoxifen: how long before we know how long?辅助性他莫昔芬：我们要多久才能知道使用时长？
BMJ. 1998 May 16;316(7143):1518-9. doi: 10.1136/bmj.316.7143.1518.
9
[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].[绝经后原发性可手术乳腺癌女性的辅助抗激素治疗]
Ugeskr Laeger. 2007 Jan 22;169(4):297-9.
10
Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst. 2002 Oct 2;94(19):1504. doi: 10.1093/jnci/94.19.1504.
引用本文的文献
1
Management of primary breast cancer.原发性乳腺癌的管理
Qual Health Care. 1996 Dec;5(4):250-8. doi: 10.1136/qshc.5.4.250.
2
Adjuvant treatment with tamoxifen. Informed consent and follow up in aTTom trial are inadequate.他莫昔芬辅助治疗。aTTom试验中的知情同意和随访不充分。
BMJ. 1996 Aug 24;313(7055):494. doi: 10.1136/bmj.313.7055.494.
3
Adjuvant treatment with tamoxifen. Care is necessary.他莫昔芬辅助治疗。需谨慎。
BMJ. 1996 Aug 24;313(7055):493-4. doi: 10.1136/bmj.313.7055.493c.
4
Adjuvant treatment with tamoxifen. Multicentre trial should be welcomed.他莫昔芬辅助治疗。多中心试验值得欢迎。
BMJ. 1996 Apr 20;312(7037):1037. doi: 10.1136/bmj.312.7037.1037.
5
Adjuvant treatment with tamoxifen. Clinicians must share knowledge with their patients more readily.他莫昔芬辅助治疗。临床医生必须更及时地与患者分享知识。
BMJ. 1996 Apr 20;312(7037):1037. doi: 10.1136/bmj.312.7037.1037a.
6
Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue.他莫昔芬辅助治疗。评估最佳治疗持续时间的研究招募工作必须继续。
BMJ. 1996 Apr 20;312(7037):1036-7. doi: 10.1136/bmj.312.7037.1036b.
7
Adjuvant treatment with tamoxifen. Side effects may have been overstated.他莫昔芬辅助治疗。其副作用可能被夸大了。
BMJ. 1996 Apr 20;312(7037):1036. doi: 10.1136/bmj.312.7037.1036.
8
Adjuvant treatment with tamoxifen. Local research ethics committees should review their approval of prevention trial.他莫昔芬辅助治疗。当地研究伦理委员会应重新审查其对预防试验的批准。
BMJ. 1996 Apr 20;312(7037):1036. doi: 10.1136/bmj.312.7037.1036a.
本文引用的文献
1
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.他莫昔芬对健康绝经前和绝经后女性通过双能X线吸收法测量的骨密度的影响。
J Clin Oncol. 1996 Jan;14(1):78-84. doi: 10.1200/JCO.1996.14.1.78.
2
A risk-benefit assessment of tamoxifen therapy.他莫昔芬治疗的风险效益评估。
Drug Saf. 1993 May;8(5):381-97. doi: 10.2165/00002018-199308050-00005.
3
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.影响淋巴结阴性乳腺癌预后的因素：对767例T1N0M0/T2N0M0患者进行长期随访的分析
J Clin Oncol. 1993 Nov;11(11):2090-100. doi: 10.1200/JCO.1993.11.11.2090.
4
Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.早期乳腺癌辅助他莫昔芬治疗与第二原发性恶性肿瘤。斯德哥尔摩乳腺癌研究小组。
J Natl Cancer Inst. 1995 May 3;87(9):645-51. doi: 10.1093/jnci/87.9.645.
5
Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy.
Cancer. 1990 Jul 15;66(2):199-205. doi: 10.1002/1097-0142(19900715)66:2<199::aid-cncr2820660202>3.0.co;2-l.
6
Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group.
Acta Oncol. 1992;31(2):251-7. doi: 10.3109/02841869209088911.
Zotero 插件